港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

靖因藥業（臨時代碼）

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

靖因藥業IPO：32項重大專利未獲授權靠非經常損益扭虧只是曇花一現？

靖因藥業衝擊IPO，聚焦小核酸創新藥領域，尚未有產品獲批

騰訊參股靖因藥業港股IPO：核心產品尚處臨床階段II期，部分研發依賴合作方

靖因藥業闖關港交所，兩年合計虧損6.5億元

新股前瞻|近9億美元BD疊加重磅siRNA療法，靖因藥業能否敲開港交所大門？

小核酸公司靖因藥業港交所遞表：上半年扭虧，暫無商業化產品收入

新股消息 | 靖因藥業遞表港交所，以siRNA療法賦能慢性病管理範式轉變

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91273/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"91273","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","market":"HK","secType":"STK","nameCN":"靖因藥業（臨時代碼）","latestPrice":0,"timestamp":1774497600000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"午間休市","change":0,"latestTime":"03-26 12:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774501200000},"marketStatusCode":3,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91273\",,,,,undefined,":{"symbol":"91273","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91273\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91273\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91273\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91273\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583526498","title":"靖因藥業IPO：32項重大專利未獲授權 靠非經常損益扭虧只是曇花一現 ？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526498","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583526498?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 13:38","pubTimestamp":1763098680,"startTime":"0","endTime":"0","summary":"　　近日，靖因药业正式向港交所递交了上市申请，高盛、海通国际及汇丰担任联席保荐人。招股书显示，靖因药业成立于2021年，致力于siRNA疗法开发。知识产权方面，多项核心专利悬而未决，技术护城河尚未建成。　　此外，截至最后可行日期，靖因药业拥有65项专利和专利申请，但其中仅有一项“多核苷酸构建体”专利获得授权。包括32项对集团业务而言属重大的专利在全球均处于“待决”状态。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkanu9175307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91273"],"gpt_icon":0},{"id":"2581001744","title":"靖因藥業衝擊IPO，聚焦小核酸創新藥領域，尚未有產品獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001744","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001744?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 17:19","pubTimestamp":1762334385,"startTime":"0","endTime":"0","summary":"两年半亏损6.16亿元","market":"us","thumbnail":"https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/3373a-96b9ebbd-26fe-43d3-97c1-7fca2215368e.jpg?guru_height=927&guru_width=1608&guru_size=135992"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3137174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","06978","91273","BK1574"],"gpt_icon":0},{"id":"2577371626","title":"騰訊參股靖因藥業港股IPO：核心產品尚處臨床階段II期，部分研發依賴合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2577371626","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577371626?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 16:54","pubTimestamp":1761209646,"startTime":"0","endTime":"0","summary":"靖因药业致力于siRNA疗法开发，不过目前仍处于临床阶段，尚无营业收入。此后，多款siRNA药物相继成功上市，目前，全球主要市场已有7款siRNA产品获批上市。据招股书，靖因药业的主要产品资产包括SRSD107、SRSD216、SRSD384等。该产品目前正处于欧洲II期多中心临床试验阶段，并计划在中国及澳大利亚/新西兰启动另一项II期试验。未来，靖因药业能否在技术、产品等方面占据长久优势，与CRISPR等伙伴的合作效益有多大，核心产品何时实现商业化突围，都还存在变数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1761209425076239506","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2045819591.USD","LU0823038988.USD","LU0516423091.SGD","LU1282648689.USD","IE00BQXX3C00.GBP","LU0588545904.SGD","LU1211504680.USD","LU0348816934.USD","LU1719994722.HKD","LU0456842615.SGD","LU0918141887.USD","LU0348827113.USD","91273","LU0823041008.USD","IE00B0169N27.USD","IE0032834883.USD","LU0577902611.USD","LU0823426480.USD","LU0441854154.USD","TCHmain","LU0348735423.USD","IE00BGV7N243.SGD","LU0823426308.USD","LU2462611646.USD","SGXZ99366536.SGD","IE00B5MMRT66.SGD","LU0823039010.USD","LU1504937902.USD","HTCD.SI","IE00B0JY6N72.USD","IE0032431581.USD","LU0675040207.SGD","LU2106854487.HKD","BK1610","LU0634319403.HKD","LU1008478684.HKD","LU1048596156.SGD","LU0072913022.USD","BK1609","LU2237443465.HKD","LU1481107354.HKD","LU0320764755.SGD","LU0862451753.SGD","LU0132412106.USD","LU1974910355.USD","LU0449509016.USD","SG9999002463.SGD","LU2778985437.USD"],"gpt_icon":1},{"id":"2573694679","title":"靖因藥業闖關港交所，兩年合計虧損6.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573694679","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573694679?lang=zh_tw&edition=fundamental","pubTime":"2025-10-05 11:53","pubTimestamp":1759636380,"startTime":"0","endTime":"0","summary":"　　港交所官网信息显示，靖因药业9月28日递交招股书，高盛、海通国际、汇丰为联席保荐人。靖因药业于2021年由OrbiMed Entities及 Creacion Ventures联合创立，是一家创新生物技术公司，聚焦新一代核酸创新疗法在心血管疾病领域的开发。靖因药业获此轮融资后估值为2.53亿美元。　　控股股东方面，OrbiMed实体是靖因药业的控股股东。62岁的冀群升持有靖因药业5.87%的股权，并担任公司的执行董事兼首席执行官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/2025-10-05/doc-infsvfqr5327789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91273","HEXmain"],"gpt_icon":0},{"id":"2571309783","title":"新股前瞻|近9億美元BD疊加重磅siRNA療法，靖因藥業能否敲開港交所大門？","url":"https://stock-news.laohu8.com/highlight/detail?id=2571309783","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571309783?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 23:04","pubTimestamp":1759158280,"startTime":"0","endTime":"0","summary":"今年9月2日，诺华与Arrowhead就siRNA疗法ARO-SNCA达成一项2亿美元首付款以及后续高达20亿美元潜在里程碑付款的BD交易。实际上，早在今年5月，全球基因编辑巨头CRISPR Therapeutics斥资8.95亿美元与国内创新药企靖因药业达成重磅合作，携手推进siRNA创新疗法的开发。也正是因此BD履历在前，让靖因药业的港股IPO备受关注。而在良好的临床数据支撑下，SRSD107这一siRNA疗法有望获得广阔的商业化市场空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91273","HEXmain"],"gpt_icon":0},{"id":"2571305623","title":"小核酸公司靖因藥業港交所遞表：上半年扭虧，暫無商業化產品收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2571305623","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571305623?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 18:35","pubTimestamp":1759142100,"startTime":"0","endTime":"0","summary":"9月28日，靖因药业向港交所递交上市申请，由OrbiMed Entities及Creacion Ventures于2021年联合创立，设双总部于圣地亚哥和上海，聚焦siRNA领域。其核心产品SRSD107是靶向凝血因子XI的siRNA药物，处于二期临床，今年5月与CRISPR Therapeutics达成合作，预先获得2500万美元现金及价值约7000万美元股票，并有资格获超8亿美元里程碑付款。据报告，2024年全球siRNA疗法市场规模达24亿美元，预计2040年将增至503亿美元。业绩上，靖因药业暂无收入，2023、2024年亏损，2025年上半年扭亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918493197b0c513&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918493197b0c513&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1131","LU0106959298.USD","LU0651947912.USD","00388","LU0149534421.HKD","LU1734074674.USD","LU0348814723.USD","LU1282649141.HKD","LU0918141705.HKD","LU1328277881.USD","LU0169518387.USD","LU0314109678.HKD","LU0516422440.USD","LU1366334578.USD","LU1044874839.SGD","LU1481107354.HKD","LU0084288322.USD","LU0516423091.SGD","LU0594300179.USD","LU0762542818.HKD","LU0370786039.SGD","LU0918141887.USD","IE00B3T34201.USD","LU0327786744.USD","LU1242518857.USD","LU0648948544.HKD","LU0417516902.SGD","LU0140636845.USD","LU1813983027.USD","LU1044876610.USD","LU1642822792.SGD","BK1589","LU2449936058.SGD","LU1044875133.USD","LU0165289439.USD","LU1981816686.USD","LU0821914370.USD","91273","80388","LU0819123356.HKD","LU1023057109.AUD","LU1993786604.SGD","LU0516422366.SGD","HEXmain","LU0043850808.USD","LU0572944931.SGD","LU1105468828.SGD","LU1807302812.USD","LU1282649067.USD","HKXCY"],"gpt_icon":0},{"id":"2571878854","title":"新股消息 | 靖因藥業遞表港交所，以siRNA療法賦能慢性病管理範式轉變","url":"https://stock-news.laohu8.com/highlight/detail?id=2571878854","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571878854?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 07:11","pubTimestamp":1759101067,"startTime":"0","endTime":"0","summary":"招股书显示，靖因药业是一家全球临床阶段生物技术公司，致力于充分发挥siRNA疗法的临床及商业价值。公司以三大潜在重磅产品管线组合、专有siRNA技术平台及全球合作网络为战略基石，旨在通过开发针对全球巨大未满足医疗需求的同类首创与同类最优siRNA 疗法，革新慢性疾病的现行治疗标准。siRNA疗法的开发标志着医学领域直接从核酸层面解决疾病机制的根本性转变。siRNA疗法为慢性病管理带来范式转变，具备三项确定性优势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91273"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}